In Vitro Evaluation of the Activity of Imipenem-Relebactam Against 451 Recent Clinical Isolates of Bacteroides Group and Related Species

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2016 Aug 3

PMID 27480858

Citations 8

Authors

David R Snydman

Nilda V Jacobus

Laura A McDermott

Affiliations

Soon will be listed here.

Abstract

We evaluated the in vitro activity of imipenem-relebactam (imipenem-MK7655) against 451 recent clinical isolates within the Bacteroides group and related species. Relebactam did not enhance or inhibit the activity of imipenem against Bacteroides fragilis or other Bacteroides species. No synergistic or antagonistic effect was observed. The MICs of imipenem-relebactam were equal to or within one dilution of the MICs of these isolates to imipenem.

Citing Articles

Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis.

Abniki R, Tashakor A, Masoudi M, Mansury D Curr Ther Res Clin Exp. 2024; 100:100723.

PMID: 38174096 PMC: 10758719. DOI: 10.1016/j.curtheres.2023.100723.

Non-odontogenic maxillofacial infections - a 17-years retrospective cohort study.

Rasteniene R, Simenaite G, Zaleckas L, Aleksejuniene J Oral Maxillofac Surg. 2023; 28(1):425-434.

PMID: 37289303 DOI: 10.1007/s10006-023-01162-6.

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Campanella T, Gallagher J Infect Drug Resist. 2020; 13:4297-4308.

PMID: 33268997 PMC: 7701153. DOI: 10.2147/IDR.S224228.

Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria and .

El Hafi B, Rasheed S, Fayad A, Araj G, Matar G Front Microbiol. 2019; 10:933.

PMID: 31114565 PMC: 6503214. DOI: 10.3389/fmicb.2019.00933.

β-lactam/β-lactamase inhibitor combinations: an update.

Tehrani K, Martin N Medchemcomm. 2018; 9(9):1439-1456.

PMID: 30288219 PMC: 6151480. DOI: 10.1039/c8md00342d.

References

Snydman D, Jacobus N, McDermott L, Golan Y, Goldstein E, Harrell L . Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe. 2011; 17(4):147-51. DOI: 10.1016/j.anaerobe.2011.05.014. View

Hirsch E, Ledesma K, Chang K, Schwartz M, Motyl M, Tam V . In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012; 56(7):3753-7. PMC: 3393460. DOI: 10.1128/AAC.05927-11. View

Castanheira M, Mendes R, Woosley L, Jones R . Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother. 2011; 66(6):1409-11. DOI: 10.1093/jac/dkr081. View

Snydman D, Jacobus N, McDermott L, Ruthazer R, Golan Y, Goldstein E . National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother. 2007; 51(5):1649-55. PMC: 1855532. DOI: 10.1128/AAC.01435-06. View

Snydman D, Jacobus N, McDermott L, Golan Y, Hecht D, Goldstein E . Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis. 2010; 50 Suppl 1:S26-33. DOI: 10.1086/647940. View